Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue

Cancer Sci. 2015 Nov;106(11):1635-41. doi: 10.1111/cas.12769. Epub 2015 Oct 15.

Abstract

Differentiating malignant pleural mesothelioma (MPM) cells morphologically from reactive mesothelial hyperplasia cells is problematic. Homozygous deletion (HD) of p16 (CDKN2A), detected by FISH, is a good marker of malignancy and is useful to differentiate between these cells. However, the correlation between the p16 status of effusion smears and that of the underlying MPM tissues has not been investigated. We used p16-specific FISH to investigate 20 cases of MPM from which both effusion cytologic smears and histologic specimens were available. In five cases, histologic specimens included both an invasive component and surface mesothelial proliferation. In 14 cases (70%), MPM cells in both tissue sections and effusion smears were p16 HD-positive. Conversely, MPM cells in the remaining six tumors (30%) were p16 HD-negative in both tissue sections and effusion smears. For all five MPM cases with surface mesothelial proliferations and invasive components, the effusion smears, surface mesothelial proliferations, and invasive MPM components all displayed p16 deletion. Moreover, the extent to which p16 was deleted in smears highly correlated with the extent of p16 deletion in tissues. The p16 deletion percentages were also similar among smears, tissue surface proliferations, and invasive components. In cases with clinical and radiologic evidence of a diffuse pleural tumor, detection of p16 deletion in cytologic smear samples may permit MPM diagnosis without additional tissue examination. However, the absence of p16 deletion in cytologic smear samples does not preclude MPM.

Keywords: Cytology; fluorescence in situ hybridization; malignant pleural mesothelioma; p16; reactive mesothelial hyperplasia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / genetics
  • Cytogenetic Analysis*
  • Diagnosis, Differential
  • Female
  • Genes, p16*
  • Humans
  • Hyperplasia / diagnosis
  • Hyperplasia / genetics
  • In Situ Hybridization, Fluorescence
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / genetics
  • Male
  • Mesothelioma / diagnosis*
  • Mesothelioma / genetics
  • Mesothelioma, Malignant
  • Middle Aged
  • Pleural Diseases / diagnosis
  • Pleural Effusion / etiology*
  • Pleural Effusion / genetics
  • Pleural Neoplasms / diagnosis*
  • Pleural Neoplasms / genetics

Substances

  • Biomarkers, Tumor